CalciMedica reports FY2023 net loss $34.4M; cash $11.2M; CARPO topline data Q2 2024

CalciMedica, Inc.

Cash, equivalents, and short-term investments $11.2M at Dec 31, 2023; pro forma after Jan 2024 private placement ~$25.5M, funding into 2H2025.
Net loss $34.4M ($7.66 per share) for FY2023; total operating expenses $38.1M including $16.2M one-time charges from reverse merger.
CARPO Phase 2b trial of Auxora in acute pancreatitis enrollment on track; topline data expected Q2 2024.
KOURAGE Phase 2 trial for severe AKI with AHRF cleared by FDA; first patient enrollment Q2 2024, data expected 2025.
CRSPA Phase 1/2 trial for asparaginase-induced pancreatic toxicity expanded to Phase 2; initial cohort data showed fewer hospital days.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CalciMedica, Inc. reported the year ended December 31, 2023 results: net income $34.4 million, or $7.66 per share (basic and diluted), EPS $7.66 per share (basic and diluted).

Period: the year ended December 31, 2023
Net income: $34.4 million, or $7.66 per share (basic and diluted)
EPS: $7.66 per share (basic and diluted)
Result: reported results

Exact text from the filing

Net loss was $34.4 million, or $7.66 per share (basic and diluted) for the year ended December 31, 2023.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

CalciMedica, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-037609

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.